Results 81 to 90 of about 14,081 (169)

Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis

open access: yesRadiation Oncology
Background and introduction Increasing evidence suggests that a subgroup of patients with oligometastatic cancer might achieve a prolonged disease-free survival through local therapy for all active cancer lesions.
Sebastian M. Christ   +17 more
doaj   +1 more source

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients

open access: yes, 2020
Breast cancer (BC) is the principal cause of cancer-related death in women. Metastatic patients are usually treated with a systemic therapy, but clinical results are limited.
Lloret, Marta   +10 more
core   +1 more source

Management of oligometastatic triple-negative breast cancer with lung metastasis using 4DCT: a case report

open access: yesJournal of Current Oncology and Medical Sciences
Introduction: Breast cancer remains the most prevalent disease in women. Oligometastatic breast cancer (OMBC), is defined by a limited disease burden. 40% of Triple negative breast cancer are associated with Lung metastasis.
Siddharth Arora, Kriti Grover
doaj  

Stereotactic ablative radiotherapy (SABR) for liver metastases: where we currently stand

open access: yesESMO Gastrointestinal Oncology
Stereotactic ablative radiotherapy (SABR), which is already used as the standard-of-care treatment in other cancers such as lung, is being increasingly used in the treatment of liver metastases in the oligometastatic setting in unresectable, pre-treated ...
S.H.R. Kim, M.K. Harrison
doaj   +1 more source

Radiotherapy of Oligometastatic Cancers

open access: yes
: The enhanced multidisciplinary treatment approach and the widespread use of advanced imaging techniques have led to an improvement in survival rates, inevitably associated with an increase in the number of oligometastatic diagnoses in cancer patients [.
Alongi, Filippo   +3 more
core   +1 more source

Role of surgery in oligometastatic prostate cancer

open access: yes, 2019
Androgen deprivation therapy as single modality therapy was the standard management for oligometastatic prostate cancer (PCa). Current paradigm shifts toward a multimodality therapy approach, targeting all sites of disease, including treatment of the ...
Pocharapong Jenjitranant   +1 more
core   +1 more source

Approach to oligometastatic prostate cancer

open access: yes, 2016
Oligometastatic prostate cancer has increasingly been recognized as a unique clinical state with therapeutic implications. It has been proposed that patients with oligometastases may have a more indolent course and that outcome may be further improved ...
Vapiwala, N.   +4 more
core   +1 more source

Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer

open access: yes, 2022
Background: A uniform definition and treatment for oligometastatic esophagogastric cancer is currently lacking. However, a comprehensive definition of oligometastatic esophagogastric cancer is necessary to initiate studies on local treatment strategies ...
Nilsson, M   +23 more
core  

Stereotactic Body Radiotherapy for Oligometastatic Disease

open access: yes, 2015
Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations ...
Landau, D.   +2 more
core   +1 more source

Oligometastatic colorectal adenocarcinoma to the spleen and ovaries. [PDF]

open access: yes
In the context of colorectal cancer, splenic and ovarian metastases are rare outside of widely disseminated disease. Growing evidence suggests that 'oligometastatic' or limited metastatic disease can be treated surgically with good oncological outcomes ...
Yang, T   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy